Views & Analysis Healthcare evidence development: guilty until proven innocen... Pharma must prepare its case meticulously to support its new drug applications.
Views & Analysis Regulatory consultants: facilitators or obstructors? External regulatory consultants can bring broad experience and expedite approvals.
Events Partner Content Joint 23rd Medicines for Europe – 20th IGBA Annual Conferenc... The Joint 23rd Medicines for Europe – 20th IGBA Annual Conference will unite over 300 experts from the generic and biosimilar sectors to discuss market trends, innovative comm
Views & Analysis Ultra-rare disease drugs: has access in England just got har... Gaining access to ultra-orphan drugs could become much more difficult.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
